Savara Inc. (SVRA)
- Previous Close
4.1100 - Open
4.1200 - Bid 4.0700 x 800
- Ask 4.1200 x 100
- Day's Range
4.0200 - 4.2600 - 52 Week Range
2.6000 - 5.7000 - Volume
2,187,552 - Avg. Volume
880,109 - Market Cap (intraday)
565.193M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
www.savarapharma.comRecent News: SVRA
Performance Overview: SVRA
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SVRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SVRA
Valuation Measures
Market Cap
565.19M
Enterprise Value
448.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.22%
Return on Equity (ttm)
-58.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-64.49M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
143.55M
Total Debt/Equity (mrq)
21.97%
Levered Free Cash Flow (ttm)
-32.93M